Koselugo

(Selumetinib)

Koselugo

Drug updated on 11/15/2023

Dosage FormCapsule (oral: 10 mg, 25 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Product Monograph / Prescribing Information

Document TitleYearSource
Koselugo (selumetinib) Prescribing Information.2021AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses